VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
SAN FRANCISCO, Nov. 6 /PRNewswire-FirstCall/ — VIA Pharmaceuticals, Inc. , a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will hold a conference call and webcast to discuss results of the VIA-2291 Phase 2 acute coronary syndrome (ACS) and carotid endarterectomy (CEA) trials presented at the American Heart Association (AHA) Scientific Sessions 2008 on Sunday, November 9. The conference call and webcast will take place on Monday, November 10, at 8:30 a.m. ET (7:30 a.m. CT).
To participate in the conference call, please dial 888-684-1280 for domestic callers and 913-312-0952 for international callers. A telephone replay of the conference call will be available through Friday, November 14, 2008. To access the replay, please dial 888-203-1112 for domestic callers and 719-457-0820 for international callers and reference conference replay passcode 1268443.
In addition, interested parties may access a live audio webcast of the presentation from the investor section of the VIA website, http://www.viapharmaceuticals.com/. A replay of the presentation will be archived on the VIA website for 30 days following the presentation.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company’s lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com/.
VIA Pharmaceuticals, Inc.
CONTACT: James G. Stewart, Senior Vice President and Chief FinancialOfficer of VIA Pharmaceuticals, Inc., +1-415-283-2204, or Media, DanielleBertrand, of WeissComm Partners, +1-415-946-1056, email@example.com; orInvestors, San Francisco, Ian Clements or Lauren Glaser, +1-415-392-3385, orNew York City, Brian Korb, +1-646-378-2923, all of The Trout Group, all forVIA Pharmaceuticals, Inc.
Web site: http://www.viapharmaceuticals.com/